MXCT / MaxCyte, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

As filed with the Securities and Exchange Commission on August 26, 2025

As filed with the Securities and Exchange Commission on August 26, 2025 Registration No.

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 MAXCYTE, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.01 par value per share Other 11,319,000 $ 1.40 $ 15,846,600.00 0.0001531 $ 2,426.11 2 Equity Common St

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 MaxCyte, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 MaxCyte, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00

Three Months Ended

Exhibit 99.1 MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance ROCKVILLE, MD, August 6, 2025 — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2

Disclaimer 2 © 2025 MaxCyte, Inc. All Rights Reserved The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”), as amended. Reliance on

Exhibit 99.2 are registered trademarks of MaxCyte, Inc. in the U.S.A. Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT August 2025 © 2025 MaxCyte, Inc. All Rights Reserved Disclaimer 2 © 2025 MaxCyte, Inc. All Rights Reserved The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Finan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 MaxCyte, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 MaxCyte, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 MaxCyte, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 MaxCyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40674 52-2210438 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 MaxCyte, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 MaxCyte, Inc.

Amended and Restated 2022 Plan

Exhibit 10.1 MAXCYTE, INC. 2022 EQUITY INCENTIVE PLAN Amended and Restated: June 18, 2025 1. GENERAL. (a) Defined Terms. Except as otherwise provided, any capitalized term shall have the meaning provided in Section 14 of this Plan. (b)Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0

Consulting Agreement, dated February 1, 2025, between Ross Squared Consulting, LLC and the Registrant.

Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is by and between MaxCyte, Inc., a Delaware corporation, having its place of business located at 9713 Key West Avenue, Suite 400, Rockville, MD 20850 (“MaxCyte”), and Ross Squared Consulting LLC, an individual, having its address at [*] (“Consultant”) is effective as of February 1, 2025 (the “Effective Date”). RECITALS W

Severance Agreement, dated as of July 1, 2024, by and between the Ali Soleymannezhad and the Registrant.

Exhibit 10.2 AMENDED AND RESTATED SEVERANCE AGREEMENT THIS SEVERANCE AGREEMENT is made as of July 1, 2024 (the “Effective Date”), by and between MaxCyte, Inc., a Delaware corporation (the “Company”), and Ali Soleymannezhad (the “Executive”). WHEREAS, the Company considers it essential to its best interests and to the best interests of its shareholders and customers to foster the continuous employm

Three Months Ended

Exhibit 99.1 MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 MaxCyte, Inc. (Exact na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 MaxCyte, Inc.

2 Disclaimer The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”), as amended. Reliance on this document for the purpose of engaging

Exhibit 99.2 ® ® ® ® TM is a trademark of MaxCyte, Inc. are registered trademarks of MaxCyte, Inc. in the U.S.A. Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT • LSE: MXCT May 2025 2 Disclaimer The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets Act

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40

Share dealing code of MaxCyte, Inc.

Exhibit 19.2 SHARE DEALING CODE MAXCYTE, INC. (the “Company”) SHARE DEALING CODE This Share Dealing Code (this “Code”) is designed to ensure that you do not misuse, or place yourself under suspicion of misusing, information about the Company and its subsidiaries (together, the “Company”) which you have and which is not available to other investors in relation to dealing in any shares or debt secur

Corporate Disclosure Policy of MaxCyte, Inc.

Exhibit 19.1 MAXCYTE, INC. CORPORATE DISCLOSURE POLICY INTRODUCTION MAXCYTE, INC. (the “Company”) and its subsidiaries (the Company and its subsidiaries together, the “Group”) is adopting this Corporate Disclosure Policy (the “Policy”) to prevent selective disclosure of “material nonpublic information” and/or “inside information” regarding the Company and to establish guidelines for disclosure of

2 Disclaimer The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”), as amended. Reliance on this document for the purpose of engaging

Exhibit 99.2 ® ® ® ® TM is a trademark of MaxCyte, Inc. are registered trademarks of MaxCyte, Inc. in the U.S.A. Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT • LSE: MXCT March 2025 2 Disclaimer The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets Ac

Subsidiaries of the Registrant.

Exhibit 21.1 List of Subsidiaries of MaxCyte, Inc. Name Jurisdiction of Incorporation or Organization CCTI, Inc. United States SeQure DX Inc. United States

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 MaxCyte, Inc.

Three Months Ended

Exhibit 99.1 MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance ROCKVILLE, MD, March 11, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourt

Amended and Restated Severance Agreement, dated as of March 10, 2025, by and between Douglas J. Swirsky, and the Registrant.

Exhibit 10.18 AMENDED AND RESTATED SEVERANCE AGREEMENT THIS SEVERANCE AGREEMENT is made as of March 10, 2025 (the “Effective Date”), by and between MaxCyte, Inc., a Delaware corporation (the "Company"), and Douglas J. Swirsky (the "Executive"). WHEREAS, the Company considers it essential to its best interests and to the best interests of its shareholders and customers to foster the continuous empl

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

Exhibit 99.1 MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments ROCKVILLE, MD – January 30, 2025 – MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the acquisition o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 MaxCyte, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 MaxCyte, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 MaxCyte, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 MaxCyte, Inc.

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Exhibit 99.1 MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results ROCKVILLE, MD, January 13, 2025 — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update

Resignation Letter, dated December 22, 2024

Exhibit 10.1 December 22, 2024 Board of Directors MaxCyte, Inc. 9713 Key West Ave #400 Rockville, MD 20850 Attn: Richard Douglas, Ph.D. Dear Richard, This letter will serve as my notice that I will be retiring as a member of the Board of Directors of MaxCyte and all Board committees, effective on December 31, 2024. This decision comes after much reflection and consideration of my personal and prof

MaxCyte Announces Retirement of Board Member Art Mandell

Exhibit 99.1 MaxCyte Announces Retirement of Board Member Art Mandell ROCKVILLE, MD, December 22, 2024 — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Art Mandell has retired from his position as a me

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2024 MaxCyte, Inc.

Regulation FD Disclosure, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 MaxCyte, Inc.

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

Exhibit 99.1 MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance ROCKVILLE, MD, December 9, 2024 — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of an internal operation

MXCT / MaxCyte, Inc. / CADIAN CAPITAL MANAGEMENT, LP Passive Investment

SC 13G/A 1 formsc13ga-maxcyte.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MaxCyte, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 57777K106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 MaxCyte, Inc.

Three Months Ended

Exhibit 99.1 MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD, November 6, 2024 — MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe

2 Disclaimer The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”), as amended. Reliance on this document for the purpose of engaging

Exhibit 99.2 ® ® ® ® TM is a trademark of MaxCyte, Inc. are registered trademarks of MaxCyte, Inc. in the U.S.A. Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT • LSE: MXCT November 2024 2 Disclaimer The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets

MXCT / MaxCyte, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

SC 13G/A 1 MXCTSC13GA1October2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) MAXCYTE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 57777K106 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the appro

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2024 MaxCyte, Inc.

MaxCyte Appoints Cynthia Collins to its Board of Directors

Exhibit 99.1 MaxCyte Appoints Cynthia Collins to its Board of Directors Rockville, MD, Oct. 15, 2024 — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appo

2 Disclaimer The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”), as amended. Reliance on this document for the purpose of engaging

Exhibit 99.2 ® ® ® ® TM is a trademark of MaxCyte, Inc. are registered trademarks of MaxCyte, Inc. in the U.S.A. Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT • LSE: MXCT August 2024 2 Disclaimer The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets A

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 MaxCyte, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00

Three Months Ended

Exhibit 99.1 MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD, August 6, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 MaxCyte, Inc.

Amended and Restated 2022 Plan

Exhibit 10.1 MAXCYTE, INC. 2022 EQUITY INCENTIVE PLAN Amended and Restated: June 11, 2024 1. GENERAL. (a)Defined Terms. Except as otherwise provided, any capitalized term shall have the meaning provided in Section 14 of this Plan. (b) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may

Three Months Ended

Exhibit 99.1 MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance ROCKVILLE, MD, May 7, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today annou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

2 Disclaimer The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”), as amended. Reliance on this document for the purpose of engaging

Exhibit 99.2 ® ® ® ® TM is a trademark of MaxCyte, Inc. are registered trademarks of MaxCyte, Inc. in the U.S.A. Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT • LSE: MXCT May 2024 2 Disclaimer The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets Act

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 MaxCyte, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

MXCT / MaxCyte, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MAXCYTE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 57777K106 (CUSIP Number) MARCH 19, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sche

Separation and Consulting Agreement, dated as of December 11, 2023 by and between the Registrant and Douglas Doerfler.

Exhibit 10.20 9713 Key West Avenue Suite 400 Rockville, MD 20850 301.944.1700 Phone 301.944.1620 Direct 301.944.1703 Fax www.maxcyte.com December 11, 2023 Douglas Doerfler Via Email Re: Transition Agreement Dear Doug: This letter memorializes the transition agreement (the “Agreement”) which MaxCyte, Inc. (the “Company”) is offering to you to aid in your retirement and employment transition. 1. Ret

Amended and Restated Incentive Compensation Recoupment Policy of the Registrant

Exhibit 97 MaxCyte, Inc. Amended and Restated Incentive Compensation Recoupment Policy 1.Introduction The Board of Directors (the “Board”) of MaxCyte, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Amended and Restated Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s

Subsidiaries of the Registrant.

Exhibit 21.1 List of Subsidiaries of MaxCyte, Inc. Name Jurisdiction of Incorporation or Organization CCTI, Inc. United States

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40

Promotion Letter, dated as of December 11, 2023, by and between the Registrant and Maher Masoud

Exhibit 10.21 9713 Key West Avenue Suite 400 Rockville, MD 20850 301.944.1700 Phone 301.944.1620 Direct 301.944.1703 Fax www.maxcyte.com December 11, 2023 Maher Masoud Re: Appointment to Chief Executive Officer and Amendment to the Severance Agreement Dear Maher: Congratulations on your appointment to the role of President and Chief Executive Officer (“CEO”) of MaxCyte, Inc. (“Company”)! This lett

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 MaxCyte, Inc.

Three Months Ended December 31, (Unaudited)

Exhibit 99.1 MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance ROCKVILLE, MD, March 12, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing appl

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 MaxCyte, Inc.

1

Exhibit 99.1 MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results ROCKVILLE, MD, March 4, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today pr

GB:MXCT / MaxCyte, Inc. / Casdin Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

GB:MXCT / MaxCyte, Inc. / CADIAN CAPITAL MANAGEMENT, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

GB:MXCT / MaxCyte, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SC 13G 1 tv01425-maxcyteinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: MaxCyte Inc Title of Class of Securities: Common Stock CUSIP Number: 57777K106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Sch

GB:MXCT / MaxCyte, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) MAXCYTE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 57777K106 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursua

Severance Agreement, between the Company and Cenk Sumen

Exhibit 10.1 SEVERANCE AGREEMENT THIS SEVERANCE AGREEMENT is made as of March 10, 2023 (the “Effective Date”), by and between MaxCyte, Inc., a Delaware corporation (the "Company"), and Cenk Sumen (the "Executive"). WHEREAS, the Company considers it essential to its best interests and to the best interests of its shareholders and customers to foster the continuous employment of its key management p

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2024 MaxCyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40674 52-2210438 (State or other jurisdiction of incorporation) (Commission File Num

1

Exhibit 99.1 MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results ROCKVILLE, MD, January 8, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applicati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 MaxCyte, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 MaxCyte, Inc.

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023 Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte Maher Masoud, EVP, Head of Global Business Development and

Exhibit 99.1 MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023 Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte Maher Masoud, EVP, Head of Global Business Development and Chief Counsel, to Succeed Mr. Doerfler as President and CEO, Effective January 1, 2024 MaxCyte is reiterating 2023 expected core busines

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2023 MaxCyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40674 52-2210438 (State or other jurisdiction of incorporation) (Commission File Nu

GB:MXCT / MaxCyte Inc / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

SC 13G 1 MXCTSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MAXCYTE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 57777K106 (CUSIP Number) NOVEMBER 8, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pu

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 MaxCyte, Inc.

Three Months Ended

Exhibit 99.1 MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance ROCKVILLE, MD, November 8, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 MaxCyte, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 MaxCyte, Inc.

MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance

Exhibit 99.1 MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance ROCKVILLE, MD, October 4, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 MaxCyte, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 MaxCyte, Inc.

Three Months Ended

Exhibit 99.1 MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance ROCKVILLE, MD, August 9, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development an

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 MaxCyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40674 52-2210438 (State or other jurisdiction of incorporation) (Commission File Number

Amendment and Restatement of the MaxCyte 2022 Equity Incentive Plan

Exhibit 10.1 MaxCyte, Inc. 2022 Equity Incentive Plan Adopted by the Board of Directors: May 22, 2022 Approved by the Stockholders: June 29, 2022 Amended by the Board of Directors: April 19, 2023 Approved by the Stockholders: June 22, 2023 1.            General. (a)            Defined Terms. Except as otherwise provided, any capitalized term shall have the meaning provided in Section 14 of this Pl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 MaxCyte, Inc.

MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance

Exhibit 99.1 MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance ROCKVILLE, MD, May 10, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based resea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

Exhibit 99.1 MaxCyte Appoints Douglas Swirsky as Chief Financial Officer Rockville, MD, March 27, 2023 – MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced D

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 MaxCyte, Inc.

Severance Agreement, dated March 27, 2023, by and between the registrant and Douglas J. Swirsky

Exhibit 10.1 SEVERANCE AGREEMENT THIS SEVERANCE AGREEMENT is made as of March 27, 2023 (the “Effective Date”), by and between MaxCyte, Inc., a Delaware corporation (the "Company"), and Douglas J. Swirsky (the "Executive"). WHEREAS, the Company considers it essential to its best interests and to the best interests of its shareholders and customers to foster the continuous employment of its key mana

Deed of Lease, dated as of May 27, 2021, between Key West MD Owner LLC and Registrant.

Exhibit 10.16 DEED OF LEASE This Lease (the “Lease”) is made this day of , 2021 (the “Effective Date”), between KEY WEST MD OWNER LLC, a Delaware limited liability company (“Landlord”), and MAXCYTE, INC., a Delaware corporation (“Tenant”). Witnesseth: For and in consideration of the covenants herein contained and upon the terms and conditions herein set forth, the parties agree as follows: 1.Intro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 MaxCyte, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 MaxCyte, Inc.

Severance Agreement, dated March 8, 2017, between the Registrant and Ron Holtz

Exhibit 10.15 SEVERANCE AGREEMENT THIS SEVERANCE AGREEMENT is made as of March 8, 2017 (the "Effective Date"), by and between MaxCyte, Inc., a Delaware corporation (the "Company"), and Ronald E. Holtz (the "Executive"). WHEREAS, the Company considers it essential to its best interests and to the best interests of its shareholders and customers to foster the continuous employment of its key managem

MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results 31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue

Exhibit 99.1 MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results 31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue ROCKVILLE, MD, March 15, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, dev

Subsidiaries of the Registrant.

Exhibit 21.1 List of Subsidiaries of MaxCyte, Inc. Name Jurisdiction of Incorporation or Organization CCTI, Inc. United States

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40

Amendment to Deed of Lease, dated as of November 16, 2021, between Key West MD Owner LLC and Registrant.

Exhibit 10.17 AMENDMENT TO DEED OF LEASE THIS AMENDMENT TO DEED OF LEASE (this “Amendment”) is made this day of , 2021 (the “Effective Date”), by and between key west md owner llc, a Delaware limited liability company (“Landlord”), and MAXCYTE, INC., a Delaware corporation (“Tenant”). RECITALS: A.Landlord and Tenant entered into that certain Deed of Lease dated May 27, 2021 (the “Lease”), whereby

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 MaxCyte, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 MaxCyte, Inc.

As of December 31,

Exhibit 99.1 MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance ● Full year 2022 total revenue expected to be approximately $44.3 million, representing growth of 31% over full year 2021 ● Fourth quarter 2022 total revenue expected to be approximately $12.4 million, representing growth of 22% over fourth quarter 2021 ● Instal

GB:MXCT / MaxCyte Inc / BAMCO INC /NY/ - NONE Passive Investment

SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* MaxCyte, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 57777K106 (CUSIP Number) Calendar Year 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

GB:MXCT / MaxCyte Inc / Sofinnova Crossover I - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1) * MaxCyte, Inc. (Name of Issuer) Common stock, par value $0.01 per share (Title of Class of Securities) 57777K106 (CUSIP Number) December 31,

GB:MXCT / MaxCyte Inc / Casdin Capital, LLC Passive Investment

SC 13G/A 1 d991226013g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MaxCyte, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 57777K106 (CUSIP Number) January 5, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

MaxCyte Appoints Patrick J. Balthrop as Non-Executive Director

Exhibit 99.1 MaxCyte Appoints Patrick J. Balthrop as Non-Executive Director Rockville, MD, 1 December, 2022: MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announc

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 MaxCyte, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 9, 2022 ? ? MaxCyte, Inc.

MaxCyte Reports Third Quarter 2022 Financial Results 22% Year-Over-Year Core Business Revenue Growth in Third Quarter 2022 Reiterates 2022 Revenue Guidance

? Exhibit 99.1 ? MaxCyte Reports Third Quarter 2022 Financial Results ? 22% Year-Over-Year Core Business Revenue Growth in Third Quarter 2022 ? Reiterates 2022 Revenue Guidance ? ROCKVILLE, MD, November 9, 2022 ? MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

MaxCyte, Inc. Form of RSU Award Grant Notice (2022 Equity Incentive Plan), dated as of July 19, 2022

? ? Exhibit 10.5 MaxCyte, Inc. RSU Award Grant Notice (2022 Equity Incentive Plan) MaxCyte, Inc. (the ?Company?), pursuant to its 2022 Equity Incentive Plan (the ?Plan?) has awarded to you (the ?Participant?) the number of restricted stock units specified, and on the terms set forth, below (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions set forth herein and in the P

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 10, 2022 ? ? MaxCyte, Inc.

MaxCyte, Inc. Form of Stock Option Grant Notice (2022 Equity Incentive Plan), dated as of July 19, 2022

? ? Exhibit 10.6 MaxCyte, Inc. Stock Option Grant Notice (2022 Equity Incentive Plan) MaxCyte, Inc. (the ?Company?), pursuant to its 2022 Equity Incentive Plan (the ?Plan?), has granted to you (?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). Your Option is subject to all of the terms and conditions as set forth in this Stock Option Gra

MaxCyte, Inc. Form of Stock Option Grant Notice (2021 Inducement Plan), dated as of January 1, 2022

? ? Exhibit 10.4 MaxCyte, Inc. Stock Option Grant Notice (2021 Inducement Plan) MaxCyte, Inc. (the ?Company?), pursuant to its 2021 Inducement Plan (the ?Plan?), has granted to you (?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). Your Option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice (t

Consulting Agreement, by and between the Company and Amanda Murphy, effective as of April 15, 2022

Exhibit 10.3 EXHIBIT A ? CONSULTING AGREEMENT ? This Consulting Agreement (the ?Agreement?) by and between MaxCyte, Inc. (?Client?) and Amanda Murphy, an individual (?Consultant?) is effective as of April 15, 2022 (the ?Effective Date?). RECITALS ? WHEREAS the parties desire for the Client to engage Consultant to perform the services described herein and for Consultant to provide such services on

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Separation Agreement, by and between the Company and Amanda Murphy, dated as of May 6, 2022

Exhibit 10.2 ? 22 Firstfield Road, Suite 110 Gaithersburg, MD 20878 ? 301.944.1700 Phone 301.944.1620 Direct 301.944.1703 Fax www.maxcyte.com ? ? April 6, 2022 ? Amanda Murphy 422 Ninth Street Wilmette, IL 60091 ? Re:Separation Agreement ? Dear Amanda: ? This letter sets forth the substance of the separation agreement (the ?Agreement?) which MaxCyte, Inc. (the ?Company?) is offering to you to aid

MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results 45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30%

? Exhibit 99.1 ? MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results ? 45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 ? Raises 2022 Core Revenue Growth Guidance to Approximately 30% ? ROCKVILLE, MD, August 10, 2022 ? MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to

Form of 2022 Employee Stock Purchase Plan

? Exhibit 99.2 ? MaxCyte,?Inc. ? 2021 Employee Stock Purchase Plan ? Adopted by the Board of Directors: July?26, 2021 Approved by the Stockholders: October?29, 2021 IPO Date: July?30, 2021 ? 1. General; Purpose. ? (a)????????????The Plan provides a means by which Eligible Employees of the Company and certain eligible Employees of designated Related Corporations may be given an opportunity to purch

Filing Fee Table.

EX-FILING FEES 5 tm2220850d1ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) MaxCyte, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount o

As filed with the Securities and Exchange Commission on July 14, 2022

As filed with the Securities and Exchange Commission on July 14, 2022 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 MaxCyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40674 52-2210438 (State or other jurisdiction of incorporation) (Commission File Number

MaxCyte, Inc. 2022 Equity Incentive Plan

Exhibit 10.1 MaxCyte, Inc. 2022 Equity Incentive Plan Adopted by the Board of Directors: May 22, 2022 Approved by the Stockholders: June 29, 2022 1. General. (a) Defined Terms. Except as otherwise provided, any capitalized term shall have the meaning provided in Section 14 of this Plan. (b) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted

MaxCyte Reports First Quarter Financial Results MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million

Exhibit 99.1 ? ? MaxCyte Reports First Quarter Financial Results ? MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million ? GAITHERSBURG, MD, May 9, 2022 ? MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 9, 2022 ? ? MaxCyte, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-385

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 MaxCyte, Inc.

MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue

Exhibit 99.1 MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue GAITHERSBURG, MD, April 12, 2022 ? MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeut

Description of Certain of Registrant's Securities

EXHIBIT 4.1 DESCRIPTION OF MAXCYTE, INC. COMMON STOCK The following description of the common stock of MaxCyte, Inc., or the Company, and certain provisions of the Company?s fifteenth amended and restated certificate of incorporation, or the amended and restated certificate, and amended and restated bylaws are summaries. These summaries are qualified in the entirety by reference to the provisions

Severance Agreement, dated March 8, 2017, between the Registrant and Ron Holtz

? Exhibit 10.14 ? SEVERANCE AGREEMENT ? THIS SEVERANCE AGREEMENT is made as of , 2017 (the ?Effective Date?) by and between MaxCyte, Inc., a Delaware corporation (the ?Company?), and (the ?Executive?). WHEREAS, the Company considers it essential to its best interests and to the best interests of its shareholders and customers to foster the continuous employment of its key management personnel; and

MaxCyte, Inc. Inducement Plan

? Exhibit 10.5 MaxCyte, Inc. 2021 Inducement Plan Adopted by the Board of Directors: December 15, 2021 ? 1.General. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1.

Notice of Termination of Lease Agreement, dated as of June 8, 2021, between ARE-20/22/1300 Firstfield Quince Orchard, LLC and Registrant.

Exhibit 10.15 Notice of Termination Of Lease Agreement between ARE-20/22/1300 Firstfield Quince Orchard, LLC And MaxCyte, Inc. ? June 8, 2021 ? ARE-20/22/1300 Firstfield Quince Orchard, LLC 385 E Colorado Boulevard Suite 299 Pasadena, California 91101 Attn: Larry Diamond ? Re: Termination Notice ? Dear Larry, Pursuant to the Lease Agreement by and between ARE-20/22/1300 Firstfield Quince Orchard,

Amendment to Deed of Lease, dated as of November 16, 2021, between Key West MD Owner LLC and Registrant.

Exhibit 10.17 AMENDMENT TO DEED OF LEASE THIS AMENDMENT TO DEED OF LEASE (this ?Amendment?) is made this day of , 2021 (the ?Effective Date?), by and between key west md owner llc, a Delaware limited liability company (?Landlord?), and MAXCYTE, INC., a Delaware corporation (?Tenant?). RECITALS: A.Landlord and Tenant entered into that certain Deed of Lease dated May 27, 2021 (the ?Lease?), whereby

MaxCyte Reports Fourth Quarter and Full Year Financial Results MaxCyte Provides Initial 2022 Guidance

EX-99.1 2 mxct-20220322xex99d1.htm EX-99.1 Exhibit 99.1 MaxCyte Reports Fourth Quarter and Full Year Financial Results MaxCyte Provides Initial 2022 Guidance GAITHERSBURG, MD, March 22, 2022 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generat

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): March 22, 2022 ? ? MaxCyte, Inc.

Subsidiaries of the Registrant.

Exhibit 21.1 ? List of Subsidiaries of MaxCyte, Inc. ? Name Jurisdiction of Incorporation or Organization ? ? ? ? CARMA Cell Therapies, Inc. United States ?

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Deed of Lease, dated as of May 27, 2021, between Key West MD Owner LLC and Registrant.

Exhibit 10.16 DEED OF LEASE This Lease (the ?Lease?) is made this day of , 2021 (the ?Effective Date?), between KEY WEST MD OWNER LLC, a Delaware limited liability company (?Landlord?), and MAXCYTE, INC., a Delaware corporation (?Tenant?). Witnesseth: For and in consideration of the covenants herein contained and upon the terms and conditions herein set forth, the parties agree as follows: 1.Intro

GB:MXCT / MaxCyte Inc / BAMCO INC /NY/ - NONE Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* MAXCYTE, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 57777K106 (CUSIP Number) Calendar Year 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched

Joint Filing Agreement

CUSIP NO. 57777K106 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the shares of MaxCyte, Inc. and further agree that this agreement be included as an exhibit to such filing. Ea

GB:MXCT / MaxCyte Inc / Sofinnova Crossover I - SC 13G Passive Investment

SC 13G 1 tm225855d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. ) * MaxCyte, Inc. (Name of Issuer) Common stock, par value $0.01 per share (Title of Class of Securities) 577

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2022 MaxCyte, Inc.

MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results

Exhibit 99.1 MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results ? Fourth quarter 2021 revenue expected to be greater than $10 million ? Full year 2021 revenue expected to be greater than $33.7 million ? Installed base of greater than 500 instruments ? 15 SPLs, covering more than 95 programs, of which over 15% have entered the clinic ? Precommercial mil

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 MaxCyte, Inc.

MaxCyte Reports Third Quarter Financial Results

Exhibit 99.1 MaxCyte Reports Third Quarter Financial Results GAITHERSBURG, MD, November 10, 2021 ? MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced third q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2021 MaxCyte, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 MaxCyte, Inc.

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Proxy Statement ? ? Definitive Additional Materials ? ? Soliciting Material Pursuant to ? 240.

MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections

Exhibit 99.1 MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections GAITHERSBURG, MD, September 13, 2021 ? MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic di

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 MaxCyte, Inc.

MaxCyte, Inc.

Exhibit 99.2 13-Sep-2021 MaxCyte, Inc. (MXCT.GB) Q2 2021 Earnings Call MaxCyte, Inc. (MXCT.GB) Q2 2021 Earnings Call CORPORATE PARTICIPANTS Douglas A. Doerfler Founder, President, Chief Executive Officer & Director, MaxCyte, Inc. Amanda L. Murphy Chief Financial Officer, MaxCyte, Inc. OTHER PARTICIPANTS Sean Menarguez Matt Larew Analyst-Business Intelligence, Strategy & Investor Relations, MaxCyte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

As filed with the Securities and Exchange Commission on August 5, 2021

As filed with the Securities and Exchange Commission on August 5, 2021 Registration No.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 MaxCyte, Inc.

Amended and Restated Bylaws of the Registrant.

Exhibit 3.1 Amended and Restated Bylaws of MAXCYTE, INC. (a Delaware Corporation) August 3, 2021 MAXCYTE, INC. Amended and Restated Bylaws ARTICLE I Offices Section 1. Registered Office. The registered office shall be established and maintained at the office of Corporation Service Company, 251 Little Falls Drive, in the City of Wilmington, in the County of New Castle, in the State of Delaware, 198

UK:MXCT / MaxCyte Inc / Casdin Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

13,500,000 Shares COMMON STOCK

TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)4? ?Registration Statement No. 333-257810? 13,500,000 Shares COMMON STOCK ? This is the U.S. initial public offering of shares of common stock of MaxCyte, Inc. We are offering 13,500,000 shares of our common stock at a public offering price of $13.00 per share. Prior to this offering, there has been no public market for our common stock in the United

As filed with the Securities and Exchange Commission on July 29, 2021

As filed with the Securities and Exchange Commission on July 29, 2021 Registration No.

Form 8-A (File No. 001-40674) filed with the Commission on July 27, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 MaxCyte, Inc. (Exact name of registrant as specified in its charter) Delaware 52-2210438 (State of Incorporation or Organization) (I.R.S. Employer Identification No.) 22 Firstfield Road, Suite 110

[Signature page follows.]

CORRESP 1 filename1.htm July 27, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: MaxCyte, Inc. Registration Statement on Form S-1 (File No. 333-257810) Attn: Ms. Julia Griffith Mr. Justin Dobbie Ms. Amy Geddes Ms. Linda Cvrkel Ladies and Gentlemen: Pursuant to Rule 460 under the Securities Act of 1933, as amended,

maxcyte, inc. 22 Firstfield Road, Suite 110 Gaithersburg, Maryland 20878

maxcyte, inc. 22 Firstfield Road, Suite 110 Gaithersburg, Maryland 20878 July 27, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, N.E. Washington, D.C. 20549 Attn: Amy Geddes, Linda Cvrkel, Julia Griffith and Justin Dobbie Re: MaxCyte, Inc. Registration Statement on Form S-1, as amended (File No. 333-257810) Request fo

Severance Agreement, dated January 21, 2021, between the Registrant and Amanda Murphy.

Exhibit 10.15 SEVERANCE AGREEMENT THIS SEVERANCE AGREEMENT is made as of January 21, 2021 (the “Effective Date”), by and between MaxCyte, Inc., a Delaware corporation (the "Company"), and Amanda Murphy (the "Executive"). WHEREAS, the Company considers it essential to its best interests and to the best interests of its shareholders and customers to foster the continuous employment of its key manage

Form of Underwriting Agreement.

Exhibit 1.1 [?] Shares MAXCYTE, INC. Common Stock UNDERWRITING AGREEMENT , 2021 Cowen and Company, LLC Stifel, Nicolaus & Company, Incorporated William Blair & Company, L.L.C. As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Stifel, Nicolaus & Company, Incorporated One South Street, 15th Floor Baltimore, Maryland 21202 c/o

Forms of Grant Notice, Stock Option Agreement under the 2021 Equity Incentive Plan.

Exhibit 10.6 MaxCyte, Inc. Stock Option Grant Notice (2021 Equity Incentive Plan) MaxCyte, Inc. (the ?Company?), pursuant to its 2021 Equity Incentive Plan (the ?Plan?), has granted to you (?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). Your Option is subject to all of the terms and conditions as set forth in this Stock Option Grant N

Fifteenth Amended and Restated Certificate of Incorporation.

exhibit 3.1 FifTEENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MAXCYTE, INC. Douglas A. Doerfler hereby certifies that: ONE: The original name of the Corporation is Theramed, Inc. and the date of filing the original Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware was July 31, 1998. On December 31, 2001, Theramed, Inc. changed its nam

Form of Indemnification Agreement by and between the Registrant and each director and executive officer

Exhibit 10.8 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) dated as of July , 2021, is made by and between MaxCyte, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). Recitals A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Company?s bylaws (the ?Bylaws?) requ

Severance Agreement, dated January 11, 2021, between the Registrant and Brad Calvin.

Exhibit 10.14 SEVERANCE AGREEMENT THIS SEVERANCE AGREEMENT is made as of January 11, 2021 (the ?Effective Date?), by and between MaxCyte, Inc., a Delaware corporation (the "Company"), and Brad Calvin (the "Executive"). WHEREAS, the Company considers it essential to its best interests and to the best interests of its shareholders and customers to foster the continuous employment of its key manageme

Severance Agreement, dated January 21, 2021, between the Registrant and Amanda Murphy.

Exhibit 10.13 SEVERANCE AGREEMENT THIS SEVERANCE AGREEMENT is made as of July 20, 2021 (the ?Effective Date?), by and between MaxCyte, Inc., a Delaware corporation (the "Company"), and Doug Doerfler (the "Executive"). WHEREAS, the Company considers it essential to its best interests and to the best interests of its shareholders and customers to foster the continuous employment of its key managemen

Form of 2021 Employee Stock Purchase Plan.

EX-10.7 9 tm2113965d9ex10-7.htm EXHIBIT 10.7 Exhibit 10.7 MaxCyte, Inc. 2021 Employee Stock Purchase Plan Adopted by the Board of Directors: , 2021 Approved by the Stockholders: , 2021 IPO Date: , 2021 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain eligible Employees of designated Related Corporations may be given an opportunity to purchas

Bylaws of Maxcyte, Inc. Effective March 29, 2016 TABLE OF CONTENTS

EX-3.2 4 tm2113965d9ex3-2.htm EXHIBIT 3.2 Exhibit 3.2 Bylaws of Maxcyte, Inc. Effective March 29, 2016 TABLE OF CONTENTS Page ARTICLE I CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Stockholders’ Meetings 1 2.5 Manner of Giving Notice; Affidavit of Notice 2 2.6 Q

Amended and Restated Bylaws, as currently in effect (incorporated herein by reference to Exhibit 3.3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-257810), filed with the Commission on July 9, 2021).

Exhibit 3.3 Amended and Restated Bylaws of MAXCYTE, INC. (a Delaware Corporation) July [], 2021 MAXCYTE, INC. Amended and Restated Bylaws ARTICLE I Offices Section 1. Registered Office. The registered office shall be established and maintained at the office of Corporation Service Company, 251 Little Falls Drive, in the City of Wilmington, in the County of New Castle, in the State of Delaware, 1980

As filed with the Securities and Exchange Commission on July 26, 2021.

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 26, 2021.

Form of 2021 Equity Incentive Plan.

Exhibit 10.5 MaxCyte, Inc. 2021 Equity Incentive Plan Adopted by the Board of Directors: , 2021 Approved by the Stockholders: , 2021 1. General. (a) Defined Terms. Except as otherwise provided, any capitalized term shall have the meaning provided in Section 14 of this Plan. (b) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the E

First Amendment to Sublease, dated as of September 9, 2019, between Novavax, Inc. and the Registrant.

Exhibit 10.13 FIRST AMENDMENT TO SUBLEASE This First Amendment to Sublease (“First Amendment”) is entered into as of the 9th day of September, 2019, by and between NOVAVAX, INC., a Delaware corporation (“Sublandlord”), and MAXCYTE, INC., a Delaware corporation (“Subtenant”). WITNESSETH: WHEREAS, Sublandlord and Subtenant entered into a Sublease dated as of April 11, 2017 (the “Sublease”), whereby

Power of Attorney (included on signature page to this registration statement).

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 9, 2021.

Form of Performance Stock Option Agreements under the MaxCyte, Inc. Long-Term Incentive Plan

Exhibit 10.3 OPTION NUMBER #xxx OPTIONEE: xxxxxxxxx xxxx DATE OF GRANT: xxxxxxx OPTION PRICE: xxxx Great Britain pence sterling COVERED SHARES: xxxxxxx (xxxxx) MAXCYTE, INC. LONG-TERM INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT FOR US PERSONS 1. Definitions. In this Agreement, except where the context otherwise indicates, the following definitions apply: (a) “Affiliate” means a corporation

Amended and Restated Bylaws of Registrant, as amended, as currently in effect.

Exhibit 3.3 Bylaws of Maxcyte, Inc. Effective March 29, 2016 TABLE OF CONTENTS Page ARTICLE I CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Stockholders? Meetings 1 2.5 Manner of Giving Notice; Affidavit of Notice. 2 2.6 Quorum 2 2.7 Adjourned Meeting; Notice 2 2

MaxCyte, Inc. Long-Term Incentive Plan

EX-10.1 4 tm2113965d6ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 MAXCYTE, INC. LONG - TERM INCENTIVE PLAN (Formerly known as MaxCyte, Inc. 2000 Long-Term Incentive Plan) Amended and Restated as of May 17, 2016 1. Definitions. In this Plan, except where the context otherwise indicates, the following definitions shall apply: 1.1 “Affiliate” means a corporation that is a parent or subsidiary corporation of

Form of New Hire Stock Option Agreements under the MaxCyte, Inc. Long-Term Incentive Plan

Exhibit 10.2 OPTION NUMBER #xxx OPTIONEE: xxxxxxxxx xxxx DATE OF GRANT: xxxxxxx GRANT REFERENCE DATE: xxxxxxxx OPTION PRICE: xxxx Great Britain pound sterling COVERED SHARES: xxxxxxx (xxxxx) MAXCYTE, INC. LONG-TERM INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT FOR US PERSONS 1. Definitions. In this Agreement, except where the context otherwise indicates, the following definitions apply: (a)

Form of Director Stock Option Agreements under the MaxCyte, Inc. Long-Term Incentive Plan

Exhibit 10.4 OPTION NUMBER #xxx OPTIONEE: xxxxxxxxx xxxx DATE OF GRANT: xxxxxxx OPTION PRICE: xxxx Great Britain pence sterling COVERED SHARES: xxxxxxx (xxxxx) MAXCYTE, INC. LONG-TERM INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT FOR US PERSONS 1. Definitions. In this Agreement, except where the context otherwise indicates, the following definitions apply: (a) “Affiliate” means a corporation

* * * *

Brian F. Leaf (703) 456-8053 [email protected] VIA EDGAR July 9, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, N.W. Washington, DC 20549 Attn: Amy Geddes Linda Cvrkel Sonia Bednarowski Justin Dobbie Re: MaxCyte, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted May 14, 2021 CIK No. 0001287098 Ladies and

Sublease, dated as of September 9, 2019, between Novavax, Inc. and the Registrant.

Exhibit 10.11 SUBLEASE This Sublease (“Sublease”) is made as of the 9th day of September, 2019 (the “Effective Date”), by and between Novavax, Inc., a Delaware corporation (“Sublandlord”), and MaxCyte, Inc., a Delaware corporation (“Subtenant”). WITNESSETH WHEREAS, Sublandlord is the “Tenant” under a certain Lease Agreement dated November 18, 2011, as amended by the First Amendment to Lease Agreem

First Amendment to Sublease, dated as of September 9, 2019, between Novavax, Inc. and the Registrant.

Exhibit 10.12 FIRST AMENDMENT TO SUBLEASE This First Amendment to Sublease (“First Amendment”) is entered into as of the 9th day of September, 2019, by and between NOVAVAX, INC., a Delaware corporation (“Sublandlord”), and MAXCYTE, INC., a Delaware corporation (“Subtenant”). WITNESSETH: WHEREAS, Sublandlord and Subtenant entered into a Sublease dated as of April 11, 2017 (the “Sublease”), whereby

Eighth Amendment to Lease Agreement, dated as of September 27, 2019, between ARE-20/22/1300 Firstfield Quince Orchard, LLC and the Registrant.

Exhibit 10.10 EIGHTH AMENDMENT TO LEASE AGREEMENT THIS EIGHTH AMENDMENT TO LEASE AGREEMENT (“this Eighth Amendment”) is made as of September 27, 2019 (“Eighth Amendment Effective Date”), by and between ARE-20/22/1300 FIRSTFIELD QUINCE ORCHARD, LLC, a Delaware limited liability company, having an address at 385 E Colorado Boulevard, Suite 299, Pasadena, California 91101 (“Landlord”), and MAXCYTE, I

Fourteenth Amended and Restated Certificate of Incorporation of Registrant, as amended, as currently in effect.

Exhibit 3.1 FOURTEENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MAXCYTE, INC. Douglas A. Doerfler hereby certifies that: ONE: The original name of the Corporation is Theramed, Inc. and the date of filing the original Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware was July 31, 1998. On December 31, 2001, Theramed, Inc. changed its na

MAXCYTE, INC. LONG - TERM INCENTIVE PLAN (Formerly known as MaxCyte, Inc. 2000 Long-Term Incentive Plan) Amended and Restated as of May 17, 2016

EX-10.1 4 filename4.htm Exhibit 10.1 MAXCYTE, INC. LONG - TERM INCENTIVE PLAN (Formerly known as MaxCyte, Inc. 2000 Long-Term Incentive Plan) Amended and Restated as of May 17, 2016 1. Definitions. In this Plan, except where the context otherwise indicates, the following definitions shall apply: 1.1 “Affiliate” means a corporation that is a parent or subsidiary corporation of the Company, as defin

MAXCYTE, INC. LONG-TERM INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT FOR US PERSONS

EX-10.4 7 filename7.htm Exhibit 10.4 OPTION NUMBER #xxx OPTIONEE: xxxxxxxxx xxxx DATE OF GRANT: xxxxxxx OPTION PRICE: xxxx Great Britain pence sterling COVERED SHARES: xxxxxxx (xxxxx) MAXCYTE, INC. LONG-TERM INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT FOR US PERSONS 1. Definitions. In this Agreement, except where the context otherwise indicates, the following definitions apply: (a) “Affili

FIRST AMENDMENT TO SUBLEASE

EX-10.13 11 filename11.htm Exhibit 10.13 FIRST AMENDMENT TO SUBLEASE This First Amendment to Sublease (“First Amendment”) is entered into as of the 9th day of September, 2019, by and between NOVAVAX, INC., a Delaware corporation (“Sublandlord”), and MAXCYTE, INC., a Delaware corporation (“Subtenant”). WITNESSETH: WHEREAS, Sublandlord and Subtenant entered into a Sublease dated as of April 11, 2017

As confidentially submitted to the Securities and Exchange Commission on June 25, 2021 as Amendment No. 1 to the initial confidential submission. This draft registration statement has not been publicly filed with the Securities and Exchange Commissio

TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on June 25, 2021 as Amendment No.

FIRST AMENDMENT TO SUBLEASE

EX-10.12 10 filename10.htm Exhibit 10.12 FIRST AMENDMENT TO SUBLEASE This First Amendment to Sublease (“First Amendment”) is entered into as of the 9th day of September, 2019, by and between NOVAVAX, INC., a Delaware corporation (“Sublandlord”), and MAXCYTE, INC., a Delaware corporation (“Subtenant”). WITNESSETH: WHEREAS, Sublandlord and Subtenant entered into a Sublease dated as of April 11, 2017

* * * *

Brian F. Leaf (703) 456-8053 [email protected] VIA EDGAR June 25, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, N.W. Washington, DC 20549 Attn: Amy Geddes Linda Cvrkel Sonia Bednarowski Justin Dobbie Re: MaxCyte, Inc. Draft Registration Statement on Form S-1 Submitted May 14, 2021 CIK No. 0001287098 Ladies and Gentlemen: On beh

[SIGNATURE PAGE FOLLOWS]

EX-10.11 9 filename9.htm Exhibit 10.11 SUBLEASE This Sublease (“Sublease”) is made as of the 9th day of September, 2019 (the “Effective Date”), by and between Novavax, Inc., a Delaware corporation (“Sublandlord”), and MaxCyte, Inc., a Delaware corporation (“Subtenant”). WITNESSETH WHEREAS, Sublandlord is the “Tenant” under a certain Lease Agreement dated November 18, 2011, as amended by the First

FOURTEENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MAXCYTE, INC.

EX-3.1 2 filename2.htm Exhibit 3.1 FOURTEENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MAXCYTE, INC. Douglas A. Doerfler hereby certifies that: ONE: The original name of the Corporation is Theramed, Inc. and the date of filing the original Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware was July 31, 1998. On December 31, 2001, Theram

Bylaws of Maxcyte, Inc. Effective March 29, 2016 TABLE OF CONTENTS

Exhibit 3.3 Bylaws of Maxcyte, Inc. Effective March 29, 2016 TABLE OF CONTENTS Page ARTICLE I CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Stockholders? Meetings 1 2.5 Manner of Giving Notice; Affidavit of Notice. 2 2.6 Quorum 2 2.7 Adjourned Meeting; Notice 2 2

MAXCYTE, INC. LONG-TERM INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT FOR US PERSONS

EX-10.3 6 filename6.htm Exhibit 10.3 OPTION NUMBER #xxx OPTIONEE: xxxxxxxxx xxxx DATE OF GRANT: xxxxxxx OPTION PRICE: xxxx Great Britain pence sterling COVERED SHARES: xxxxxxx (xxxxx) MAXCYTE, INC. LONG-TERM INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT FOR US PERSONS 1. Definitions. In this Agreement, except where the context otherwise indicates, the following definitions apply: (a) “Affili

MAXCYTE, INC. LONG-TERM INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT FOR US PERSONS

EX-10.2 5 filename5.htm Exhibit 10.2 OPTION NUMBER #xxx OPTIONEE: xxxxxxxxx xxxx DATE OF GRANT: xxxxxxx GRANT REFERENCE DATE: xxxxxxxx OPTION PRICE: xxxx Great Britain pound sterling COVERED SHARES: xxxxxxx (xxxxx) MAXCYTE, INC. LONG-TERM INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT FOR US PERSONS 1. Definitions. In this Agreement, except where the context otherwise indicates, the following

EIGHTH AMENDMENT TO LEASE AGREEMENT

EX-10.10 8 filename8.htm Exhibit 10.10 EIGHTH AMENDMENT TO LEASE AGREEMENT THIS EIGHTH AMENDMENT TO LEASE AGREEMENT (“this Eighth Amendment”) is made as of September 27, 2019 (“Eighth Amendment Effective Date”), by and between ARE-20/22/1300 FIRSTFIELD QUINCE ORCHARD, LLC, a Delaware limited liability company, having an address at 385 E Colorado Boulevard, Suite 299, Pasadena, California 91101 (“L

As confidentially submitted to the Securities and Exchange Commission on May 14, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential.

TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on May 14, 2021.